|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BRIEF DEFINITIVE REPORT |
CORRESPONDENCE Naoki Matsumoto: nmatsu{at}k.u-tokyo.ac.jp
|
|
|---|
KLRG1 is an orphan C-type lectin-like receptor that was originally identified as the mast cell functionassociated antigen (MAFA) expressed on the rat basophilic leukemia cell line RBL-2H3 (7). Antibody-mediated ligation of KLRG1 inhibits release of inflammatory mediators from RBL-2H3 cells induced by cross-linking of Fc
RI. In contrast, in mouse and human, KLRG1 is expressed on subsets of NK cells and T cells (812). In normal mice,
30% of resting NK cells express KLRG1, and viral infections increase the percentage of KLRG1-expressing NK cells (13). In humans,
60% of NK cells from healthy adult donors express KLRG1 (14). Although T cell expression of KLRG1 in normal mice is restricted to small subpopulations of effectormemory type T cells (11, 12, 15), expression of KLRG1 is up-regulated in mouse CD8+ T cells by infection with pathogens (12, 16). In humans, KLRG1 is expressed on
40% of CD8+ T cells and
20% of CD4+ T cells from healthy adult donors (14). Furthermore, over 90% of CD8+ T cells specific to CMV or EBV express KLRG1 during the latent stages of these chronic infections (17). Consistent with the inhibitory activity in RBL-2H3 cells (7), KLRG1 has an immune receptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain, and mAb-mediated cross-linking of KLRG1 inhibits NK cell function (13). Although rat KLRG1 has been shown to bind saccharides (7), endogenous ligands for KLRG1 have not been identified.
To identify endogenous KLRG1 ligands, we generated a KLRG1 tetramer and a KLRG1 reporter cell line, which allowed us to identify cell lines expressing KLRG1 ligands. By expression cloning using the KLRG1 tetramer as a probe, we identify human E-cadherin as a xenogeneic ligand. We also show that mouse KLRG1 binds three members of the mouse classical cadherin family and KLRG1 binding by its ligand inhibits NK cell cytotoxicity.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
|
|
5-kb DNA fragment, which encoded human E-cadherin, a Ca2+-dependent adhesion molecule that plays pivotal roles in tissue morphogenesis and in the formation of cellular junctions (18, 19). Consistent with these data, a mAb to human E-cadherin stained the KLRG1 tetramer-positive population (Fig. 2 D). The biochemical nature of E-cadherin, such as sensitivity to trypsin-EDTA treatment, the apparent migration on SDS-PAGE, and the presence of a single intramolecular disulfide bond, is also consistent with that of the putative KLRG1 ligand expressed on EBC-1 cells. To confirm a syngeneic interaction between KLRG1 and E-cadherin, mouse E-cadherin was expressed on BW5147 cells (Fig. 3 A). BW5147 cells expressing mouse E-cadherin bound the mouse KLRG1 tetramer and stimulated the mouse KLRG1 reporter cells (Fig. 3, A and B). In the complementary experiment, a dodecameric form of a mouse E-cadherinFc fusion protein was used to stain BW5147 cells transduced with mouse KLRG1 using a bicistronic expression vector carrying cDNA for expression of an EGFP marker. The E-cadherinFc fusion protein stained the EGFP+ KLRG1+ cells, and the staining was blocked by a mAb against KLRG1 (Fig. 3, C and D). Conversely, the E-cadherinFc fusion protein did not stain the EGFP-negative population of KLRG1 transductants or control transductants. Collectively, these results indicate that KLRG1 binds E-cadherin.
|
|
Eß7 integrin (21). Thus, classical cadherins function both as ligands and as receptors in mediating cellcell adhesion. Our results reveal a novel function of the cadherins as ligands for an inhibitory receptor expressed on immune cells.
Binding of KLRG1 by E-cadherin inhibits NK cell cytotoxicity
Because KLRG1 has an ITIM consensus sequence in its cytoplasmic region and mAb-mediated cross-linking of KLRG1 inhibits NK cell functions (13), we investigated the functional consequence of the KLRG1 receptor binding to its ligand. We expressed KLRG1 in the mouse NK cell line NK03 (Fig. 5 A), which does not normally express KLRG1, and examined its capacity to kill F9 cells, which express E-, N-, and R-cadherins. The KLRG1-expressing NK cells killed F9 cells less efficiently than the uninfected control NK cells, and the antimouse KLRG1 mAb restored the cytotoxicity of the KLRG1 expressing NK cells to levels similar to that of the control NK cells (Fig. 5 B). We also tested killing of the E-cadherinexpressing BW5147 cells by the same effectors. The KLRG1-expressing NK cells again showed a reduced capacity to kill E-cadherinexpressing targets, and the reduction was abolished by addition of an anti-KLRG1 mAb (Fig. 5 C). These results indicate that E-cadherin binding to KLRG1 on NK cells inhibits NK cell cytotoxicity.
|
Normally, classical cadherins are localized at tight junctions in epithelia and similar structures in endothelia, both of which form the physical barriers. Migration of leukocytes through these barriers is regulated by chemokines, whose action is modulated by the inhibitory receptor Ly49A in NK cells (24). In this context, KLRG1 may regulate transendothelial migration of NK and T cells that express KLRG1. Similar localization at the tight junctions has been observed for the poliovirus receptor (CD166). CD166 recognition by DNAM-1, an activating receptor expressed on NK cells, as well as other leukocytes, is involved in the transendothelial migration of monocytes (25). Further studies using KLRG1-deficient animals or in vivo blocking of KLRG1 function using mAbs against KLRG1 will provide insight into the physiological function of KLRG1.
The malignancy of epithelial tumors is often associated with down-regulation of E-cadherin, which makes tumor cells invasive and metastatic (26, 27). Because our results predict that tumor cells lacking E-cadherin expression would be more prone to killing by KLRG1+ NK cells, it is tempting to hypothesize that NK cells expressing KLRG1 are instrumental in surveillance of malignant tumors. This idea is analogous to the advocated role of inhibitory MHC class I receptors in surveillance of tumor cells that have lost or down-regulated MHC class I expression in the "missing self hypothesis" (28). Although KLRG1 expression on NK cells is inducible by viral infections (13), there is also a compartment of NK cells that constitutively express KLRG1, which dominates
30% of mouse resting NK cells and
50% of human peripheral blood NK cells (8, 9, 14, 22, 29). The KLRG1+ subsets of resting NK cells may be involved in surveillance of malignant tumors that have lost their "identity" by losing or down-regulating the expression of E-, N-, or R-cadherins, although this hypothesis needs validation by in vivo studies.
Finally, our results uncover a novel role of the classical cadherins, which are ubiquitously expressed among solid tissues and have a fundamental role in maintaining morphology of the solid tissues in vertebrates, in which these proteins are used to regulate the cytotoxicity of cells of the innate and acquired immune systems.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Culture supernatant from hybridoma cells obtained from M. Takeichi (Institute of Physical and Chemical Research CDB, Hyogo, Japan) was used to provide the rat antiE-cadherin (ECCD-2) mAb. The other mAbs used were a mouse monoclonal antihuman E-cadherin (67A4; Santa Cruz Biotechnology, Inc.) and a hamster monoclonal antimouse KLRG1 (2F1; eBioscience).
For flow cytometry, PE-antimouse IgG F(ab')2 or FITC-antimouse IgG F(ab')2 fragments were used as the secondary reagents. Data were acquired with a FACSCalibur system and were analyzed with CellQuest software (BD Biosciences).
Preparation of biotinylated KLRG1 protein and its tetramer.
A cDNA encoding the ectodomain of mouse KLRG1 amplified by RT-PCR from C57BL/6J spleen cells was cloned into pET3Nbio (30). Expression, refolding, biotinylation, and tetramerization of the KLRG1 ectodomain were performed as described previously (30). The tetramer was used at 2.55 µg/ml for staining.
KLRG1 reporter assays.
The construct for the KLRG1 chimeric receptor, muKLRG1rep-pMXs-IG, included the extracellular and transmembrane regions of the mouse KLRG1 and the cytoplasmic region of the mouse CD3
chain. The muKLRG1rep-pMXs-IG vector and the empty pMXs-IRES-GFP vector were used for transduction of the BWZ.36 cell line to establish the reporter BWZ.muKLRG1 and the control BWZ.EGFP, respectively. The cell lines were cultured with the indicated target cells for 16 h, and ß-galactosidase activity was determined by colorimetric assay using chlorophenol red-ß-D-galactopyranoside (Wako) as a substrate.
Precipitation and detection of a putative KLRG1 ligand.
KLRG1 ligands were precipitated from lysates of EBC-1 cells that had been surface labeled with 125I using streptavidin-agarose beads loaded with the biotinylated mouse KLRG1 protein. The precipitates were analyzed on a 10% SDS-PAGE gel, and the gel was subjected to phosphorimaging with a BAS-2500 system (Fuji Photo Film).
Expression cloning.
A cDNA library containing 1.4 x 106 independent clones was constructed using the pMXs vector and used for transduction of BW5147 cells. The cells positive for the KLRG1 tetramer were enriched by three rounds of sorting with a FACSVantage SE. Genomic DNA extracted from the enriched population was used for the recovery of the cDNA inserts by PCR amplification with primers specific for the pMXs vector. The amplified cDNA fragments were cloned into the pBluescript II SK(+) vector (Stratagene) and sequenced.
Transduction with cadherins or KLRG1.
cDNAs for mouse E- and N-cadherins were provided by M. Takeichi (Institute of Physical and Chemical Research CDB, Hyogo, Japan). cDNA for mouse P-cadherin was obtained from the Institute of Physical and Chemical Research BioResource Center (Ibaraki, Japan). cDNAs for R-, VE-, and M-cadherin were amplified by RT-PCR from the brain of a C57BL/6J mouse and from C2C12 cells, respectively. These cDNAs were independently subcloned into a pMXs vector or a pMXs-IRES-EGFP vector and used for retroviral transduction. A BW5147 cell line expressing E-cadherin was established from BW5147 cells transduced with the pMXs vector with E-cadherin cDNA by limiting dilution.
Preparation of E-cadherinFc fusion protein.
Preparation of the E-cadherinFc fusion protein will be described elsewhere (unpublished data). In brief, cDNA fragments encoding the extracellular region of mouse E-cadherin and the Fc segment of human IgG1 fused with an IgA tail piece (a gift from H. Arase, Osaka University, Osaka, Japan) were cloned into a pRc/CMV1 vector (Invitrogen). 293T cells were transfected with a 5:1 mixture of the E-cadherinFc expression vector and an expression vector for mouse furin (pCMVmFur; a gift from K. Nakayama, Kyoto University, Kyoto, Japan), and the culture supernatants containing 0.2 µg/ml of E-cadherinFc protein were used to stain cells for 30 min at 37°C, followed by staining with PE-goat antihuman IgG Fc antibody preabsorbed with hamster serum. Where indicated, cells were incubated with 10 µg/ml of hamster antimouse KLRG1 mAb (2F1) or control hamster antibody, before staining with E-cadherinFc fusion protein.
Cytotoxicity assays.
The mouse NK cell line NK03, which was established from spleen NK cells of C57BL/6J mice in our laboratory (unpublished data), was transduced with mouse KLRG1 cDNA subcloned into the pMXs-IRES-EGFP vector. The cells with high levels of EGFP expression were sorted using a FACSVantage SE. The cytotoxicity of NK cells against various target cells was examined using a standard 4 h 51Cr-release assay, as described (30). Where indicated, 5 µg/ml of the indicated mAb was included in the assays. F9 cells and BW5147 cells lack expression of Fc
receptors, excluding the possibility of reverse antibody-dependent cell cytotoxicity.
Online supplemental material.
Table S1 lists the cell lines used to identify the KLRG1 ligands. Fig. S1 describes the sensitivity of the putative KLRG1 ligand(s) to trypsin-EDTA treatment. Fig. S2 describes RT-PCR analysis for expression of cadherins in mouse cell lines. Fig. S3 describes expression of cadherins on BW5147 cells transduced with various cadherins. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20051986/DC1.
| Acknowledgments |
|---|
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and a grant from the Mochida Memorial Foundation for Medical and Pharmaceutical Research.
The authors have no conflicting financial interests.
Submitted: 4 October 2005
Accepted: 10 January 2006
| References |
|---|
|
|
|---|
1 Biron, C.A., K.B. Nguyen, G.C. Pien, L.P. Cousens, and T.P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:189220.[CrossRef][Medline]
2 Lanier, L.L. 2005. NK cell recognition. Annu. Rev. Immunol. 23:225274.[CrossRef][Medline]
3 Long, E.O. 1999. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17:875904.[CrossRef][Medline]
4 Moretta, L., and A. Moretta. 2004. Killer immunoglobulin-like receptors. Curr. Opin. Immunol. 16:626633.[CrossRef][Medline]
5 Yokoyama, W.M. 1998. Natural killer cell receptors. Curr. Opin. Immunol. 10:298305.[CrossRef][Medline]
6 Kumar, V., and M.E. McNerney. 2005. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat. Rev. Immunol. 5:363374.[CrossRef][Medline]
7 Abramson, J., R. Xu, and I. Pecht. 2002. An unusual inhibitory receptorthe mast cell function-associated antigen (MAFA). Mol. Immunol. 38:13071313.[CrossRef][Medline]
8 Blaser, C., M. Kaufmann, and H. Pircher. 1998. Virus-activated CD8 T cells and lymphokine-activated NK cells express the mast cell function-associated antigen, an inhibitory C-type lectin. J. Immunol. 161:64516454.
9 Hanke, T., L. Corral, R.E. Vance, and D.H. Raulet. 1998. 2F1 antigen, the mouse homolog of the rat "mast cell function-associated antigen", is a lectin-like type II transmembrane receptor expressed by natural killer cells. Eur. J. Immunol. 28:44094417.[CrossRef][Medline]
10 Butcher, S., K.L. Arney, and G.P. Cook. 1998. MAFA-L, an ITIM-containing receptor encoded by the human NK cell gene complex and expressed by basophils and NK cells. Eur. J. Immunol. 28:37553762.[CrossRef][Medline]
11 Beyersdorf, N.B., X. Ding, K. Karp, and T. Hanke. 2001. Expression of inhibitory "killer cell lectin-like receptor G1" identifies unique subpopulations of effector and memory CD8 T cells. Eur. J. Immunol. 31:34433452.[CrossRef][Medline]
12 Voehringer, D., C. Blaser, P. Brawand, D.H. Raulet, T. Hanke, and H. Pircher. 2001. Viral infections induce abundant numbers of senescent CD8 T cells. J. Immunol. 167:48384843.
13 Robbins, S.H., K.B. Nguyen, N. Takahashi, T. Mikayama, C.A. Biron, and L. Brossay. 2002. Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J. Immunol. 168:25852589.
14 Voehringer, D., M. Koschella, and H. Pircher. 2002. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood. 100:36983702.
15 Kaech, S.M., J.T. Tan, E.J. Wherry, B.T. Konieczny, C.D. Surh, and R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4:11911198.[CrossRef][Medline]
16 McMahon, C.W., A.J. Zajac, A.M. Jamieson, L. Corral, G.E. Hammer, R. Ahmed, and D.H. Raulet. 2002. Viral and bacterial infections induce expression of multiple NK cell receptors in responding CD8+ T cells. J. Immunol. 169:14441452.
17 Ibegbu, C.C., Y.X. Xu, W. Harris, D. Maggio, J.D. Miller, and A.P. Kourtis. 2005. Expression of killer cell lectin-like receptor G1 on antigen-specific human CD8+ T lymphocytes during active, latent, and resolved infection and its relation with CD57. J. Immunol. 174:60886094.
18 Takeichi, M. 1991. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 251:14511455.
19 Vleminckx, K., and R. Kemler. 1999. Cadherins and tissue formation: integrating adhesion and signaling. Bioessays. 21:211220.[CrossRef][Medline]
20 Tang, A., M.S. Eller, M. Hara, M. Yaar, S. Hirohashi, and B.A. Gilchrest. 1994. E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J. Cell Sci. 107(Pt 4):983992.[Abstract]
21 Cepek, K.L., S.K. Shaw, C.M. Parker, G.J. Russell, J.S. Morrow, D.L. Rimm, and M.B. Brenner. 1994. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the
Eß7 integrin. Nature. 372:190193.[CrossRef][Medline]
22 Corral, L., T. Hanke, R.E. Vance, D. Cado, and D.H. Raulet. 2000. NK cell expression of the killer cell lectin-like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules. Eur. J. Immunol. 30:920930.[CrossRef][Medline]
23 Raulet, D.H., R.E. Vance, and C.W. McMahon. 2001. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19:291330.[CrossRef][Medline]
24 Inngjerdingen, M., B. Rolstad, and J.C. Ryan. 2003. Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12. J. Immunol. 171:28892895.
25 Reymond, N., A.M. Imbert, E. Devilard, S. Fabre, C. Chabannon, L. Xerri, C. Farnarier, C. Cantoni, C. Bottino, A. Moretta, et al. 2004. DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J. Exp. Med. 199:13311341.
26 Takeichi, M. 1993. Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell Biol. 5:806811.[CrossRef][Medline]
27 Birchmeier, W., K.M. Weidner, J. Hulsken, and J. Behrens. 1993. Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas. Semin. Cancer Biol. 4:231239.[Medline]
28 Karre, K., H.G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature. 319:675678.[CrossRef][Medline]
29 Robbins, S.H., M.S. Tessmer, T. Mikayama, and L. Brossay. 2004. Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection. J. Immunol. 173:259266.
30 Matsumoto, N., M. Mitsuki, K. Tajima, W.M. Yokoyama, and K. Yamamoto. 2001. The functional binding site for the C-type lectin-like natural killer cell receptor Ly49A spans three domains of its major histocompatibility complex class I ligand. J. Exp. Med. 193:147158.
Related Articles
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|